{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T23:51:54Z","timestamp":1788911514590,"version":"build-2803163510"},"reference-count":51,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1097\/tp.0000000000000613","type":"journal-article","created":{"date-parts":[[2015,2,20]],"date-time":"2015-02-20T18:51:22Z","timestamp":1424458282000},"page":"1869-1875","source":"Crossref","is-referenced-by-count":47,"title":["Donor-Specific Anti-HLA Antibodies and Endothelial C4d Deposition\u2014Association With Chronic Liver Allograft Failure"],"prefix":"10.1097","volume":"99","author":[{"given":"Speranta","family":"Iacob","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito R.","family":"Cicinnati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Lindemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Falko M.","family":"Heinemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold","family":"Radtke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gernot M.","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iyad","family":"Kabar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut H. J.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo A.","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Beckebaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"5","key":"R1-21-20210129","first-page":"505","article-title":"The long-term liver graft and protocol biopsy: do we want to look What will we find Curr Opin Organ T","volume":"16","author":"Ekong","year":"2011","journal-title":"ransplant"},{"issue":"1","key":"R2-21-20210129","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/TP.0b013e31829434d4","article-title":"Early versus late acute antibody-mediated rejection in renal transplant recipients.","volume":"96","author":"Dorje","year":"2013","journal-title":"Transplantation"},{"issue":"1","key":"R3-21-20210129","first-page":"48","article-title":"Pre-transplant donor specific antibody and its clinical significance in kidney transplantation.","volume":"30","author":"Thammanichanond","year":"2012","journal-title":"Asian Pac J Allergy Immunol"},{"issue":"4","key":"R4-21-20210129","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1097\/MOT.0b013e3283626149","article-title":"Posttransplant monitoring of de novo human leukocyte antigen donor-specific antibodies in kidney transplantation.","volume":"18","author":"Wiebe","year":"2013","journal-title":"Curr Opin Organ Transplant"},{"issue":"9","key":"R5-21-20210129","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1111\/j.1600-6143.2011.03593.x","article-title":"High mean fluorescence intensity donor-specific anti-HLA antibodies associated with chronic rejection Postliver transplant.","volume":"11","author":"OLeary","year":"2011","journal-title":"Am J Transplant"},{"issue":"12","key":"R6-21-20210129","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/j.healun.2011.07.012","article-title":"Role of morphologic parameters on endomyocardial biopsy to detect sub-clinical antibody-mediated rejection in heart transplantation.","volume":"30","author":"Fedrigo","year":"2011","journal-title":"J Heart Lung Transplant"},{"issue":"4","key":"R7-21-20210129","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.healun.2009.10.003","article-title":"Increased erythrocyte C4D is associated with known alloantibody and autoantibody markers of antibody-mediated rejection in human lung transplant recipients.","volume":"29","author":"Golocheikine","year":"2010","journal-title":"J Heart Lung Transplant"},{"issue":"Suppl 24","key":"R8-21-20210129","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1399-0012.2012.01642.x","article-title":"Significance of C4d deposition in antibody-mediated rejection.","volume":"26","author":"Takeda","year":"2012","journal-title":"Clin Transplant"},{"issue":"3","key":"R9-21-20210129","first-page":"447","article-title":"C4d in liver allografts: a sign of antibody-mediated rejection Am J T","volume":"6","author":"Colvin","year":"2006","journal-title":"ransplant"},{"issue":"3","key":"R10-21-20210129","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1600-6143.2005.01180.x","article-title":"C4d in acute rejection after liver transplantationa valuable tool in differential diagnosis to hepatitis C recurrence.","volume":"6","author":"Schmeding","year":"2006","journal-title":"Am J Transplant"},{"issue":"6","key":"R11-21-20210129","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/lt.23403","article-title":"Sinusoidal C4d deposits in liver allografts indicate an antibody-mediated response: diagnostic considerations in the evaluation of liver allografts.","volume":"18","author":"Kozlowski","year":"2012","journal-title":"Liver Transpl"},{"issue":"4","key":"R12-21-20210129","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/lt.22233","article-title":"Liver allograft antibody-mediated rejection with demonstration of sinusoidal C4d staining and circulating donor-specific antibodies.","volume":"17","author":"Kozlowski","year":"2011","journal-title":"Liver Transpl"},{"issue":"12","key":"R13-21-20210129","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1111\/j.1600-6143.2006.01554.x","article-title":"Isolated donor specific alloantibody-mediated rejection after ABO compatible liver transplantation.","volume":"6","author":"Watson","year":"2006","journal-title":"Am J Transplant"},{"issue":"3","key":"R14-21-20210129","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/j.1600-6143.2010.03414.x","article-title":"The significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation.","volume":"11","author":"Musat","year":"2011","journal-title":"Am J Transplant"},{"issue":"Suppl 1","key":"R15-21-20210129","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1399-0039.2006.758_5.x","article-title":"Typing of potential and selected donors for transplant: methodology and resolution.","volume":"69","author":"Oudshoorn","year":"2007","journal-title":"Tissue Antigens"},{"issue":"4","key":"R16-21-20210129","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1159\/000228834","article-title":"HLA genotyping and antibody characterization using the luminex multiplex technology.","volume":"36","author":"Heinemann","year":"2009","journal-title":"Transfus Med Hemother"},{"issue":"12","key":"R17-21-20210129","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1097\/00000478-199512000-00007","article-title":"Chronic hepatitis. An update on terminology and reporting.","volume":"19","author":"Batts","year":"1995","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"R18-21-20210129","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/MOT.0b013e3283614a10","article-title":"Impact of donor-specific antibodies on results of liver transplantation.","volume":"18","author":"OLeary","year":"2013","journal-title":"Curr Opin Organ Transplant"},{"issue":"4","key":"R19-21-20210129","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/lt.22474","article-title":"Implications of a positive crossmatch in liver transplantation: a 20-year review.","volume":"18","author":"Ruiz","year":"2012","journal-title":"Liver Transpl"},{"issue":"12","key":"R20-21-20210129","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.3109\/00365521.2013.845795","article-title":"Influence of preformed donor-specific antibodies and C4d on early liver allograft function.","volume":"48","author":"Perera","year":"2013","journal-title":"Scand J Gastroenterol"},{"issue":"9","key":"R21-21-20210129","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1111\/j.1600-6143.2005.01016.x","article-title":"Serial ten-year follow-up of HLA and MICA antibody production prior to kidney graft failure.","volume":"5","author":"Mizutani","year":"2005","journal-title":"Am J Transplant"},{"issue":"3","key":"R23-21-20210129","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/TP.0b013e31827d62e3","article-title":"Incidence and impact of de novo donor-specific alloantibody in primary renal allografts.","volume":"95","author":"Everly","year":"2013","journal-title":"Transplantation"},{"issue":"5","key":"R24-21-20210129","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/j.1600-6143.2012.04013.x","article-title":"Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant.","volume":"12","author":"Wiebe","year":"2012","journal-title":"Am J Transplant"},{"issue":"6","key":"R25-21-20210129","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1111\/ajt.12212","article-title":"De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients.","volume":"13","author":"Kaneku","year":"2013","journal-title":"Am J Transplant"},{"issue":"11","key":"R26-21-20210129","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/lt.23534","article-title":"Progressive graft fibrosis and donor-specific human leukocyte antigen antibodies in pediatric late liver allografts.","volume":"18","author":"Miyagawa-Hayashino","year":"2012","journal-title":"Liver Transpl"},{"issue":"3","key":"R27-21-20210129","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/lt.21981","article-title":"Human leukocyte antigen crossmatch testing is important for liver retransplantation.","volume":"16","author":"Goh","year":"2010","journal-title":"Liver Transpl"},{"issue":"8","key":"R28-21-20210129","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/j.1432-2277.2009.01022.x","article-title":"Prevalence of anti-HLA antibodies after liver transplantation.","volume":"23","author":"Fontana","year":"2010","journal-title":"Transpl Int"},{"issue":"11","key":"R29-21-20210129","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/j.1432-2277.2011.01312.x","article-title":"Long-term follow up for anti-HLA donor specific antibodies postrenal transplantation: high immunogenicity of HLA class II graft molecules.","volume":"24","author":"Ntokou","year":"2011","journal-title":"Transpl Int"},{"issue":"9","key":"R30-21-20210129","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1002\/lt.23687","article-title":"Preformed class II donor-specific antibodies are associated with an increased risk of early rejection after liver transplantation.","volume":"19","author":"OLeary","year":"2013","journal-title":"Liver Transpl"},{"issue":"8","key":"R31-21-20210129","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/j.1399-3046.2012.01781.x","article-title":"Humoral immunity is involved in the development of pericentral fibrosis after pediatric live donor liver transplantation.","volume":"16","author":"Yamada","year":"2012","journal-title":"Pediatr Transplant"},{"issue":"1","key":"R32-21-20210129","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1055\/s-0029-1192058","article-title":"Unique aspects of rejection and tolerance in liver transplantation.","volume":"29","author":"Knechtle","year":"2009","journal-title":"Semin Liver Dis"},{"issue":"1","key":"R33-21-20210129","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0168-8278(90)90264-R","article-title":"Major histocompatibility complex antigens in human liver transplants.","volume":"11","author":"Steinhoff","year":"1990","journal-title":"J Hepatol"},{"issue":"7","key":"R34-21-20210129","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/ki.2011.497","article-title":"Pros and cons for C4d as a biomarker.","volume":"81","author":"Cohen","year":"2012","journal-title":"Kidney Int"},{"issue":"4","key":"R35-21-20210129","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.trim.2009.06.004","article-title":"Vascular deposition of complement C4d is increased in liver allografts with chronic rejection.","volume":"21","author":"Martelius","year":"2009","journal-title":"Transpl Immunol"},{"issue":"7","key":"R36-21-20210129","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.humpath.2007.12.014","article-title":"An immunohistochemical evaluation of C4d deposition in pediatric inflammatory liver diseases.","volume":"39","author":"Bouron-Dal Soglio","year":"2008","journal-title":"Hum Pathol"},{"issue":"6","key":"R37-21-20210129","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/lt.23854","article-title":"Donor-specific alloantibodies are associated with fibrosis progression after liver transplantation in hepatitis C virus-infected patients.","volume":"20","author":"OLeary","year":"2014","journal-title":"Liver Transpl"},{"issue":"1","key":"R38-21-20210129","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/01.tp.0000267916.36343.ca","article-title":"Predictors of graft and patient survival in hepatitis C virus (HCV) recipients: model to predict HCV cirrhosis after liver transplantation.","volume":"84","author":"Iacob","year":"2007","journal-title":"Transplantation"},{"issue":"1","key":"R39-21-20210129","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1046\/j.1523-1755.2002.00425.x","article-title":"Immune responsiveness in renal transplant recipients: mycophenolic acid severely depresses humoral immunity in vivo.","volume":"62","author":"Rentenaar","year":"2002","journal-title":"Kidney Int"},{"issue":"1","key":"R40-21-20210129","first-page":"139","article-title":"Mycophenolate mofetil: safety and efficacy in the prophylaxis of acute kidney transplantation rejection.","volume":"5","author":"Dalal","year":"2009","journal-title":"Ther Clin Risk Manag"},{"issue":"2","key":"R41-21-20210129","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1093\/ndt\/gfk027","article-title":"Tacrolimus combined with mycophenolate mofetil can effectively reverse C4d-positive steroid-resistant acute rejection in Chinese renal allograft recipients.","volume":"21","author":"Sun","year":"2006","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"R42-21-20210129","doi-asserted-by":"crossref","first-page":"4244","DOI":"10.1016\/j.transproceed.2005.10.015","article-title":"Late developing C4d-positive humoral renal allograft rejection associated with withdrawal of mycophenolate mofetil.","volume":"37","author":"Sun","year":"2005","journal-title":"Transplant Proc"},{"issue":"4","key":"R43-21-20210129","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1097\/TP.0b013e3181b0e608","article-title":"Mycophenolic acid impedes the antigen presenting and lymph node homing capacities of human blood myeloid dendritic cells.","volume":"88","author":"Cicinnati","year":"2009","journal-title":"Transplantation"},{"issue":"2","key":"R44-21-20210129","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/j.1600-6143.2004.00706.x","article-title":"MMF and calcineurin taper in recurrent hepatitis C after liver transplantation: impact on histological course.","volume":"5","author":"Bahra","year":"2005","journal-title":"Am J Transplant"},{"issue":"1-3","key":"R45-21-20210129","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejphar.2012.05.001","article-title":"Mycophenolate mofetil inhibits macrophage infiltration and kidney fibrosis in long-term ischemia-reperfusion injury.","volume":"688","author":"Jiang","year":"2012","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"R46-21-20210129","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1432-2277.2011.01228.x","article-title":"Long-term, maintenance MMF monotherapy improves the fibrosis progression in liver transplant recipients with recurrent hepatitis C.","volume":"24","author":"Manzia","year":"2011","journal-title":"Transpl Int"},{"issue":"2","key":"R47-21-20210129","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1124\/jpet.106.117051","article-title":"In vitro evidence for a direct antifibrotic role of the immunosuppressive drug mycophenolate mofetil.","volume":"321","author":"Roos","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"R48-21-20210129","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1016\/j.transproceed.2009.06.152","article-title":"Combined mycophenolate mofetil and minimal dose calcineurin inhibitor therapy in liver transplant patients: clinical results of a prospective randomized study.","volume":"41","author":"Beckebaum","year":"2009","journal-title":"Transplant Proc"},{"issue":"9","key":"R49-21-20210129","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1111\/j.1365-2036.2007.03466.x","article-title":"Clinical trial: switch to combined mycophenolate mofetil and minimal dose calcineurin inhibitor in stable liver transplant patientsassessment of renal and allograft function, cardiovascular risk factors and immune monitoring.","volume":"26","author":"Cicinnati","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"R50-21-20210129","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/lt.20453","article-title":"Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis C.","volume":"11","author":"Wiesner","year":"2005","journal-title":"Liver Transpl"},{"issue":"11","key":"R51-21-20210129","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1053\/jlts.2003.50269","article-title":"Impact of immunosuppression on immunopathogenesis of liver damage in hepatitis C virus-infected recipients following liver transplantation.","volume":"9","author":"McCaughan","year":"2003","journal-title":"Liver Transpl"},{"issue":"10","key":"R52-21-20210129","doi-asserted-by":"crossref","first-page":"465","DOI":"10.5414\/CPP41465","article-title":"Review of the antiproliferative properties of mycophenolate mofetil in non-immune cells.","volume":"41","author":"Morath","year":"2003","journal-title":"Int J Clin Pharmacol Ther"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000000613","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T07:18:21Z","timestamp":1620976701000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007890-201509000-00021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":51,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000000613","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]}}}